Share Name Share Symbol Market Type
Johnson and Johnson NYSE:JNJ NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.21 -0.13% 166.89 168.72 166.3165 167.20 4,045,391 20:52:04

Johnson & Johnson Unit Seeks FDA OK of Stelara for Juvenile Psoriatic Arthritis

08/10/2021 1:48pm

Dow Jones News

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

From Jul 2021 to Jan 2022

Click Here for more Johnson and Johnson Charts.

By Colin Kellaher


Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Friday said it has filed for U.S. Food and Drug Administration expanded approval of its anti-inflammatory drug Stelara to treat children ages five and older with juvenile psoriatic arthritis.

The company said it expects a decision from the FDA late next year.

The FDA first approved Stelara in September 2009 for adults with moderate to severe plaque psoriasis. The drug has since been cleared for children with plaque psoriasis and for adults with psoriatic arthritis, Crohn's disease and ulcerative colitis.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

October 08, 2021 08:33 ET (12:33 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Johnson and Johnson Chart

1 Year Johnson and Johnson Chart

1 Month Johnson and Johnson Chart

1 Month Johnson and Johnson Chart
ADVFN Advertorial
Your Recent History
Johnson an..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220119 21:06:59